Related Experiment Video

Updated: Jul 17, 2025

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge
09:53

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge

Published on: June 15, 2018

7.4K

Extracellular Vesicle MicroRNAs in Heart Failure: Pathophysiological Mediators and Therapeutic Targets

Changhai Tian1, Jessica N Ziegler1, Irving H Zucker2

  • 1Department of Toxicology and Cancer Biology, University of Kentucky, Lexington, KY 40536, USA.

Cells
|September 8, 2023
PubMed

Insights

Extracellular vesicles (EVs) carrying microRNAs (miRNAs) are key in heart failure. These EV-miRNAs show promise as biomarkers and therapeutic targets for cardiovascular diseases.

Area of Science:

  • Cardiovascular Diseases
  • Molecular Biology
  • Biochemistry

Background:

  • Extracellular vesicles (EVs) mediate intercellular communication in cardiovascular diseases (CVDs).
  • MicroRNAs (miRNAs) within EVs play a role in heart failure (HF) progression.
  • EV and miRNA biogenesis, and miRNA sorting into EVs, are tightly regulated processes.

Purpose of the Study:

  • To review the role of EV-associated miRNAs in heart failure.
  • To explore the potential of EV-miRNAs as diagnostic and prognostic biomarkers for HF.
  • To discuss the therapeutic applications of EV-miRNAs in heart failure.

Main Methods:

  • This review synthesizes current research on EV-miRNAs in HF.
  • Literature search on miRNA biogenesis, EV sorting, and HF pathogenesis.
  • Analysis of studies investigating EV-miRNA biomarkers and therapeutics.

Main Results:

  • EV-miRNAs are crucial mediators in heart failure development and progression.
  • Circulating EV-miRNAs demonstrate significant potential as HF biomarkers.
  • EV-miRNAs offer novel therapeutic avenues for heart failure.

Conclusions:

  • EV-miRNAs are integral to cardiovascular health and disease.
  • Targeting EV-miRNAs presents a promising strategy for HF treatment.
  • Further research into EV-miRNA mechanisms can advance HF diagnostics and therapeutics.
Keywords:
biomarkersextracellular vesiclesheart failuremicroRNAssorting mechanism

More Related Videos

Purification and Transplantation of Myogenic Progenitor Cell Derived Exosomes to Improve Cardiac Function in Duchenne Muscular Dystrophic Mice08:13

Purification and Transplantation of Myogenic Progenitor Cell Derived Exosomes to Improve Cardiac Function in Duchenne Muscular Dystrophic Mice

Published on: April 10, 2019

6.1K
Tissue-specific miRNA Expression Profiling in Mouse Heart Sections Using In Situ Hybridization08:22

Tissue-specific miRNA Expression Profiling in Mouse Heart Sections Using In Situ Hybridization

Published on: September 15, 2018

8.2K

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
15
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
460
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
12
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
418
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
16